NRX PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.32 USD | +4.40% |
|
-6.21% | -27.83% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 281.1 | 75.08 | 38.3 | 35.61 | - |
| Enterprise Value (EV) 1 | 281.1 | 75.08 | 38.3 | 35.61 | 35.61 |
| P/E ratio | -0.64 x | - | - | - | - |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | - | 9.96 x | -3.29 x | -1.24 x | -0.77 x |
| Nbr of stocks (in thousands) | 5,881 | 6,764 | 8,325 | 10,725 | - |
| Reference price 2 | 47.80 | 11.10 | 4.600 | 3.320 | 3.320 |
| Announcement Date | 3/31/22 | 3/30/23 | 3/29/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -44.4 | -27.84 | -24 | -20 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income | -93.06 | - | - | - | - |
| Net margin | - | - | - | - | - |
| EPS | -74.40 | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/31/22 | 3/30/23 | 3/29/24 | - | - |
1USD in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -9.6 | -9.141 | -9.95 | -9.435 | -8.188 | -5.808 | -4.406 | -5.998 | -6 | -6 | -6 | -5 | -5 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | -6.528 | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | -6.528 | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | -0.7400 | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/15/22 | 11/14/22 | 3/30/23 | 5/15/23 | 8/14/23 | 11/13/23 | 3/29/24 | 5/14/24 | - | - | - | - | - |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets | - | - | - | - | - |
| Book Value Per Share 1 | - | 1.120 | -1.400 | -2.680 | -4.320 |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 3/31/22 | 3/30/23 | 3/29/24 | - | - |
1USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.32
USD
Average target price
31.5
USD
Spread / Average Target
+848.80%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -27.83% | 35.61M | |
| +49.21% | 56.87B | |
| +39.98% | 39.72B | |
| -6.86% | 39.27B | |
| -4.42% | 28.73B | |
| +12.00% | 26.21B | |
| -18.27% | 19.79B | |
| +29.57% | 12.28B | |
| +25.41% | 12.23B | |
| -0.35% | 12.12B |
- Stock Market
- Equities
- BRPA Stock
- Financials NRx Pharmaceuticals, Inc.
